GLP-1 microdosing​, what to know

Recently, some people have started “microdosing” GLP-1 medicines by taking less than the recommended dosage. The idea of microdosing is that you can get the benefits, like controlling blood sugar, with fewer side effects and lower cost.

With doctor approval, this could be the right choice for some people, but GLP-1 microdosing also comes with some risks. Here’s what to know.

What is GLP-1 microdosing?

GLP-1 microdosing means taking a dose of a GLP-1 medicine, like Ozempic (semaglutide) or Mounjaro (tirzepatide), that’s smaller than the dose prescribed by your doctor.

Ozempic is a brand-name version of the medicine semaglutide. A typical starting dose of Ozempic, for example, is 0.25 milligrams per week.¹ Mounjaro is the brand-name version of the medicine tirzepatide. A typical starting dose for Mounjaro is 2.5 milligrams per week.² Microdosing involves taking an even lower dosage than this.

Why do some people consider GLP-1 microdosing?

Common reasons people explore microdosing include:

• Lowering the risk of uncomfortable side effects
• Blood sugar or appetite control
• Easing into a higher dose gradually
• Saving money by purchasing less medicine

Potential benefits of low-dose GLP-1 use

Since microdosing uses lower amounts of GLP-1 than standard, it is considered a controversial trend. But it may benefit some people.

Increasing your dosage slowly might reduce common GLP-1 side effects like nausea, indigestion or loss of appetite.³

Taking lower doses can also help you adjust to changes in dosage. When you’re using less medicine and making smaller adjustments, your body is less likely to have a dramatic response to the medicine.³

It’s also true that using less GLP-1 per dose is a cost-saving strategy. Microdosing lets you use each injection pen for longer, lowering your total cost. For people without insurance, this might be very appealing.

Risks of GLP-1 microdosing without medical guidance

Microdosing on your own isn’t recommended.

It can lead to inconsistent dosing, reduced effectiveness or accidentally taking too much medicine, which can cause extra digestive effects, including low blood sugar swings or complete loss of appetite.

Each GLP-1 injection pen has a set number of audible “clicks” per dose of medicine. Some people try to inject less medicine per dosage by counting clicks. This is called “click counting,” but injection pens aren’t designed to be used this way. Click counting is widely considered unsafe, since it can easily lead to taking too much or too little medicine for your needs.

Reducing GLP-1 side effects: What’s proven and what’s not

Nearly half of people taking GLP-1 medicines experience digestive issues such as nausea, vomiting or diarrhea.⁴ This is because these medicines work by slowing your stomach’s emptying. This changes how fast you digest food. The good news is that digestive side effects seem to go away within a few weeks to a few months for most people.⁵

Still, if these uncomfortable effects are making it hard to keep taking your medicine, microdosing could be an option to talk with your doctor about. Starting with a low GLP-1 dose and increasing it slowly might help limit digestive side effects.³

It’s very important to involve your doctor in the decision to microdose. They can help you do it safely and correctly. It’s also important to be cautious about “compounded” versions of GLP-1s. These medicines don’t go through the same safety testing as FDA-approved medicines.⁶

Before your doctor approves a lower GLP-1 dose, they may also suggest you try other strategies to control side effects. These might include⁷:

• Eating smaller, more frequent meals
• Eating more slowly
• Saying well hydrated
• Avoiding spicy or greasy foods

Cost-saving: What to discuss with your doctor

GLP-1s can be quite expensive, so it’s understandable to look for ways to bring down the cost of these medicines.

By adjusting the dosage under medical supervision, you have the added benefit to save on costs.

Your doctor’s office may be able to help you explore insurance coverage, manufacturer programs, rebates and patient support programs.

But changing doses on your own isn’t a safe way to save money. GLP-1 medicines are powerful and work best when used as prescribed.

When to talk to a doctor

Your doctor is your best resource for information about GLP-1 microdosing. If you have ongoing or worsening side effects from a standard dosage, don’t hesitate to ask them if a smaller amount of medicine could help you feel better.

If you have worries about the safety, cost or effectiveness of microdosing, mention it at your next appointment.

Takeaway

GLP-1 microdosing might be helpful for some people but never adjust your medicine without first talking with your doctor. They can help you decide if this strategy is right for you. They’re also available to talk through options for controlling common side effects like indigestion, nausea and constipation.

At Crystal Run Healthcare, our academically trained Endocrinologists treat everything from diabetes and thyroid disorders to osteoporosis. Every endocrinologist at our practice has access to the latest treatments and medical therapies available to provide each one of our patients the best possible outcome. With a proven track record of exceeding national benchmarks in managing patients with diabetes, our team stands at the front lines in the battle against endocrine disorders.

1. National Library of Medicine. Current utilization patterns of glucagon-like peptide-1 receptor agonists: Report. 2022.
2. Farzam K, et al. Tirzepatide. February 20, 2024.
3. Komé A, et al. One size does not fit all: Understanding microdosing semaglutide for diabetes in multidose pens. Diabetes Care. January 14, 2025.
4. Manne-Goehler J, et al. Side effects of GLP-1 receptor agonists. BMJ. August 4, 2024.
5. Ghusn W, et al. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. Obesity Pillars. December 2024.
6. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. February 4, 2026.
7. Gorgojo-Martinez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: A multidisciplinary expert consensus. Journal of Clinical Medicine. December 24, 2022.